

Minutes of Medicines Commissioning Committee Meeting Wednesday 9th May 2018 9.30-12pm, West Offices, York

1. Apologies / Attendance

		JUN	JUL	AUG	SEP	OCT	NOV	DEC	JAN	FEB	MAR	APR	MAY
Strategic Lead Pharmacist- MMT	Mrs Rachel Ainger (RA)	✓	✓	A	✓	✓	✓	✓	A	✓	✓	✓	✓
Chair & Vale of York CCG Pharmacist	Mrs Laura Angus (LA)	✓	✓	✓	✓	✓	✓	✓	A	A	✓	A	✓
GP Prescribing Lead – S&R CCG	Dr Greg Black (GB)	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Principal Pharmacist Formulary, Interface and Palliative Care	Mrs Jane Crewe (JEC)	✓	✓	✓	✓	✓	✓	✓	✓	A	✓	✓	✓
Consultant Anaesthetist	Dr Peter Hall (PH)	✓	A	✓	A	✓	✓	A	✓	A	✓	A	✓
Deputy Chief Pharmacist Tees Esk and Wear Mental Health Trust (TEWV)	Mr Richard Morris (RM)	✓	A	✓	A	✓	A	✓	A	A	✓	A	✓
GP Vale of York CCG	Dr William Ovenden (WO)	✓	✓	✓	✓	✓	✓	✓	A	✓	✓	✓	✓
GP Prescribing Lead – VoY CCG	Dr Shaun O’Connell (SO’C)	✓	A	✓	A	✓	A	A	✓	✓	✓	✓	✓
Deputy Chief Pharmacist	Mr Stuart Parkes (SP)	✓	A	✓	✓	A	✓	A	✓	✓	✓	A	✓
Consultant Psychiatrist (TEWV)	Dr Michelle Beaumont (MB)	A	A	A	A	A	A	A	A	A	A		A
Consultant Cardiologist	Dr Chris Hayes (CH)	✓	✓	✓	A	A	✓	A	✓	A	✓	✓	✓
Senior pharmacists Vale of York CCG	Mr Faisal Majothi (FM)					✓		✓	✓	✓	✓	✓	A
	Mr Jamal Hussain (JH)							✓	✓	✓	✓	✓	✓
Regional Drug & Therapeutics Centre, Newcastle – Professional Secretary	Mrs Elizabeth Okpara (EO)/ Mr Gavin Mankin (GM)	✓ MM EO	✓ EO	✓ MM EO	✓ MM EO	✓ MM EO	✓ MM	✓ MM EO	✓ EO	✓ EO GM	✓ GM	✓ GM	✓ GM

Item	
1	<p>General business</p> <p>Laura Angus (LA) chaired the meeting. Apologies were received from Faisal Majothi and Michelle Beaumont for the meeting today.</p> <p>Dr Mark Wakerley a GP from Haxby attended the meeting as an observer.</p>

	<p>Declarations of conflicts of interest relating to the agenda Nil declared.</p>
<p>2</p> <p>2.1</p>	<p>Matters arising</p> <p>Chairs actions to report There were no Chair's actions to report from ScR CCG or VoY CCG this month.</p> <p>Outcome of VoY SMT/SRCCG Clinical Executive Committee The ScR CCG CE committee approved the recommendations from the April 2018 MCC meeting. The VoY CCG CE committee approved the recommendations from the April 2018 MCC meetings.</p> <p>Draft minutes and matters arising from last meeting The minutes were agreed as a true record subject to the following changes under item 6.4:</p> <ul style="list-style-type: none"> • Remove word "is" from 3rd line in 2nd paragraph • Change MMC to MCC • Clarify that Hull formulary does not specify exactly which formulations of tadalafil are included <p><u>Action log/long-term matters arising</u></p> <p>Items which should not routinely be prescribed in primary care – The formulary has been updated, TEWV are currently developing a deprescribing guideline for trimipramine. Actions: RM to submit draft trimipramine deprescribing guideline when available.</p> <p>Governance – Proposed process/options for governance of decisions made by Chair's Action still in development, and conflicts for interest training for MCC members still to be arranged. Action: MMT to work-up proposed process/options for governance of decisions made by Chair's actions to come to April 2018 MCC. Action: MMT to ask CCG legal team to do some training for MCC members on conflicts of interest, their definition and how they should be managed.</p> <p>Triple combination inhalers for COPD: Trelegy® and Trimbrow® – formulary has been updated.</p> <p>Fiasp® appeal – formulary has been updated.</p> <p>Darbepoetin alfa for use in chronic renal disease – guideline for use – formulary has been updated.</p> <p>Formulary amendments agreed in March – formulary has been updated.</p> <p>Adult depression algorithm – link for final document been added to RSS website.</p> <p>Children and Young People depression algorithm – link for final document been added to RSS website.</p> <p>Benzodiazepine coroner letter – TEWV D&T did not feel an action plan was needed but have highlighted awareness of the issue within their organisation.</p> <p>Colesevelam – formulary has been updated.</p>

	<p>RAG status of dopamine agonists pramipexole and ropinirole for restless legs syndrome - formulary has been updated.</p> <p>Asthma Pathway formulary review - formulary has been updated.</p> <p>Infant formulae guidance – link has been added to RSS website.</p> <p>Hull and East Riding Prescribing Committee Minutes – LA/RA still to consider sharing MCC minutes with HERPEC, and explore scope for sharing documents as part of working across STP.</p> <p>BAD safety alert on chloroquine and hydrochloroquine - SO has written to ophthalmologists to say MCC do not support implementation of this guidance at present as concerns it is not sufficiently evidenced based. LA has asked NICE to look at this issue and was agreed that RA would ask RMOC to review Action: RA to ask RMOC to review and issue national guidance on updated monitoring for chloroquine and hydrochloroquine.</p> <p>Formulary amendments agreed in April – formulary has been updated.</p> <p>Conditions for which over the counter items should not routinely be prescribed in primary care – implementation of this guidance is being looked at as an STP wide issue. JEC is still working to identify any drugs within the current formulary that should be endorsed as OTC or consideration given to changing to BLACK status.</p> <p>RMOC briefing on Adalimumab – has been added to MCC agenda as standing agenda item.</p> <p>Formulary review Inflammatory Bowel Disease section – formulary still to be updated. New formulary submission still in progress for Salofalk liquid enema. Feedback for rationale for removing Pentasa suppositories and adding Salofalk tablets still to be confirmed.</p> <p>Glucodrate withdrawal – formulary still to be updated now CCG approved.</p> <p>Estriol 0.1% Cream (Ovestin®) formulary application - formulary still to be updated now CCG approved.</p> <p>Tadalafil Once Daily – review of RAG status – confirmed that East Riding CCG commissioning position is the same as ours.</p> <p>Overactive Bladder in women pathway – link still to be added to RSS website.</p> <p>Anticoagulant choices in non-valvular AF (updated) – link still to be added to RSS website.</p> <p>12 month audit data MCC outcomes for recommendations from Jan 2017 – MMT still to a cost analysis of Peptac vs Gaviscon, and also SGLT2-spend.</p> <p>Emollients medal ranking – link still to be added to RSS website. Agreed need to review inclusion of bath emollients in light of new evidence published in BMJ recently.</p> <p>Erectile Dysfunction medal ranking - link still to be added to RSS website.</p>
3	<p>Governance Nil this month.</p>

4	<p>Mental Health Medicines Commissioning Nil this month.</p>
5	<p>National and Regional Guidance</p> <p>5.1 Monthly NICE update (April 2018) It was agreed that the formulary would be updated to reflect NICE guidance as follows: The drugs in the following TAs to be reflected in the formulary as red drugs in the relevant chapters with links to the TAs: TA517: Avelumab for treating metastatic Merkel cell carcinoma TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</p> <p>All of the above TAs with the exception of are NHSE commissioned therefore would have no cost impact to CCGs.</p> <p>TA518: Tocilizumab for treating giant cell arteritis - The group agreed to assign a RED status for this indication in line with the NICE TA.</p> <p>The group noted that NICE had published the following guidance: NG95: Lyme disease</p> <p>Links will be added to the formulary with no further action required. The group noted that local antimicrobial guidelines are currently being updated to include NG95.</p> <p>NTAG Recommendations None for this meeting.</p> <p>RMOC Recommendations Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines The MMC noted the recommendations from the RMOC and discussed under item 5.3.</p> <p>Medicines Safety (MHRA drug safety update – April 2018) The group noted the drug safety updates for March on Obeticholic acid, and Valproate medicines. The links are to be added to the relevant sections of the formulary.</p> <p>RDTC monthly horizon scanning (April 2018) New products that have been recently launched or licensed were highlighted to the group for information.</p> <p>Action: JEC to update formulary accordingly following CCG approval.</p>
5.2	<p>MHRA Drug Safety Update – April 2018 – Valproate in pregnancy & women of child bearing potential The MCC discussed implementation of the new pregnancy prevention programme locally in light of the latest MHRA Drug Safety Update. The group noted that the alert had been circulated to all GP practices and within secondary care, but that GP practices were still to carry out an audit to identify the patients affected. Concerns were expressed about the increased workload that this will have for specialists and hence increased activity which will be a cost pressure. Concern was also raised that not all the supporting information and consent forms from the manufacturers were in place as yet.</p> <p>Action: MMT to flag to CCGs the increased cost of referrals to neurology and mental</p>

	<p>health services as a result of this new guidance.</p> <p>Action: MMT to audit potential patient numbers to gauge impact of this guidance.</p> <p>Action: RA to feedback to RMOC concerns that not all supporting information is available as yet and there is a need for national guidance on how to implement the new pregnancy prevention programme.</p>
5.3	<p>RMOC Statement on Standardising Strengths of High Risk, Unlicensed oral liquid Formulations of Anti-TB Medicines</p> <p>The recommendation from the RMOC to standardise to Ethambutol 400mg in 5ml, Pyrazinamide 500mg in 5ml and Isoniazid 50mg in 5ml was approved by the MCC.</p> <p>Action: JEC to update formulary accordingly following CCG approval.</p>
5.4	<p>Y&S MCC work plan</p> <p>The group noted the current work plan and agreed to add the following:</p> <ul style="list-style-type: none"> • Implementation of Valproate Drug Safety Update
6	<p>Formulary and Managed Entry of New Drugs</p>
6.1	<p>Bisphosphonates Medal Ranking</p> <p>The MCC approved an updated version of the Bisphosphonates Medal Ranking. The MCC also approved changing the RAG status for Zoledronic acid from RED to AMBER specialist recommendation once pathway for use in community based clinics is in place.</p> <p>It was also agreed to add to Risedronate 5mg to the Black list for new patients on grounds of cost-effectiveness.</p> <p>Action: MMT to arrange for link to document on RSS website following CCG approval.</p> <p>Action: MMT to search for numbers of patients currently prescribed Risedronate 5mg.</p> <p>Action: RDTC to complete DNP tool for Risedronate 5mg.</p>
6.2	<p>Calcium and Vitamin D Medal Ranking</p> <p>The MCC approved an updated version of the Calcium and Vitamin D Medal Ranking subject to the following change:</p> <ul style="list-style-type: none"> • Move consideration of need to prescribe these drugs at all to top of document along with calcium calculator. <p>It was also agreed to include a review of the need for bisphosphonate and Calcium/Vitamin D prescribing in the CCG de-prescribing workstream.</p> <p>Action: MMT to arrange for changes to be made and link to document on RSS website following CCG approval.</p>
6.3	<p>Kyleena® Formulary Application</p> <p>The MCC agreed that the formulary application for Kyleena® needed to go the local authority for approval as they are the commissioner for sexual health. It will then come back to the MCC for information if approved.</p> <p>Action: RA/AL to send JC contact details for new drug submissions to the local authority.</p>
6.4	<p>Topical NSAIDS Formulary Review</p> <p>The group discussed the formulary status of topical NSAIDs as none are currently listed on the locally formulary. It was agreed to develop a medal ranking for their use with a</p>

	<p>limited choice of products to be used.</p> <p>Action: MMT to develop a medal ranking document for Topical NSAIDS together with evidence for use and risks associated with use.</p>
7	Interface: Shared Care Guidelines (SCGs) and Pathways
7.1	<p>Bisphosphonates in Breast Cancer An updated version of the local Bisphosphonates in Breast Cancer pathway was presented to and approved by the MCC.</p> <p>Action: MMT link to document on RSS website following CCG approval.</p>
8	Monitoring/reporting
8.1	<p>Twelve month audit data MCC outcomes for recommendations from February 2017 The group reviewed the audit reports on cost and activity for recommendations made in January 2017.</p>
8.2	<p>Action:</p> <p>VoY Red drugs data This item is reported quarterly.</p>
8.3	<p>ScR Red drugs data This item is reported quarterly.</p>
8.4	<p>Adalimumab biosimilars implementation – update A verbal update on the introduction of adalimumab biosimilars was given to the group.</p>
9	<p>Patient and clinical communications Nothing to report.</p>
10	Items from other groups
10.1	<p>York and Scarborough Drug and Therapeutics Committee minutes None available.</p>
10.2	<p>Hull and East Riding Prescribing Committee (HERPC) – Draft minutes from March 2018 meeting None available as March 2018 meeting was cancelled.</p>
10.3	<p>Y&S Medicines Efficiency Sub-committee None available</p>
11	Any urgent business
11.1	<p><u>Esyma®</u> The MCC noted that S&R CCG are currently looking in to a patient prescribed Esyma® for an unlicensed indication on the advice of Harrogate Trust in light of the recent MHRA Drug Safety Update around Esyma®.</p>
	Date and time of next meeting: Wednesday 13th June 2018, 9:30am, Rowntree room, West Offices, York.